Canadian DIN & Molecule SearchMolecules A–ZDrug ShortagesResourcesHealth Canada WeeklyRequest a Quote

GEMFIBROZIL-600 - TAB 600MG 600 MG

GEMFIBROZIL : 600 MG · DIN 02136058 · PRO DOC LIMITEE

Health Canada status: CANCELLED POST MARKET

What is GEMFIBROZIL-600 - TAB 600MG?

GEMFIBROZIL-600 - TAB 600MG 600 MG contains GEMFIBROZIL : 600 MG. It is listed in the Health Canada Drug Product Database under DIN 02136058, held by PRO DOC LIMITEE, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 10-Jul-2015. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.

What is GEMFIBROZIL-600 - TAB 600MG used for?

Adjunct to diet for: very high serum triglycerides (Type IV/V hyperlipidemia) at risk of pancreatitis; hypercholesterolemia (Type IIa/IIb) to regulate lipid levels.

Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.

What else is GEMFIBROZIL-600 - TAB 600MG called?

The same molecule, GEMFIBROZIL, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:

NameScriptRegistered in
AusgemLatinAustralia
LipigemLatinAustralia
LOPIDLatinBahrain, Saudi Arabia
LOW-LIPLatinBahrain

Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.

Product details and regulatory record

DIN02136058
Brand nameGEMFIBROZIL-600 - TAB 600MG
Generic / active ingredientGEMFIBROZIL : 600 MG
ManufacturerPRO DOC LIMITEE
Strength600 MG
Dosage formTABLET
Route of administrationORAL
SchedulePrescription
ATC codeC10AB04 GEMFIBROZIL
AHFS class24:06.06
BiosimilarNo
Health Canada statusCANCELLED POST MARKET
Status date10-Jul-2015
Original market date1995-12-31 00:00:00

How is this product identified?

Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.

DIN (8-digit, as used in Nexara ordering)02136058
DIN (unpadded, as printed on some documents)2136058
Brand nameGEMFIBROZIL-600 - TAB 600MG
Active ingredient / INNGEMFIBROZIL : 600 MG
ATC codeC10AB04
ATC anatomical main groupC — Cardiovascular system
ATC therapeutic subgroupC10
AHFS class24:06.06
Health Canada schedulePrescription
Biosimilar biologicNo
Market authorization holderPRO DOC LIMITEE

Health Canada approved product monograph (PDF)

How is it administered?

Adults: 1200 mg daily in two divided doses (600 mg twice a day) 30 minutes before morning and evening meals. Maximum daily dose: 1500 mg.

Included because it drives pack selection and wastage. Consult the monograph.

How is it stored and handled?

Store between 15-25°C (59-77°F). Protect from moisture.

How is it supplied?

Bottles of 100 and 500 tablets; unit dose packages of 100.

Which pack is which?

Strength on the label600 MG
Dosage formTABLET
RouteORAL
Packaging as described in the monographBottles of 100 and 500 tablets; unit dose packages of 100.
StorageStore between 15-25°C (59-77°F). Protect from moisture.

One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.

Confirm the pack and get a price

Contraindications

Hepatic/renal dysfunction; gallbladder disease; hypersensitivity; pregnancy/lactation; Type I hyperlipoproteinemia; concomitant use with repaglinide.

Warnings and precautions

Risk of severe myopathy and rhabdomyolysis, especially if used with HMG-CoA reductase inhibitors. May increase cholesterol excretion leading to gallstones (cholelithiasis).

What can be used instead?

Other Canadian products sharing ATC code C10AB04 GEMFIBROZIL. 1 of 22 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.

ProductStrengthFormManufacturerHealth Canada statusDIN
TEVA-GEMFIBROZIL600 MGTABLETTEVA CANADA LIMITEDMARKETEDDIN 02142074
APO-GEMFIBROZIL600 MGTABLETAPOTEX INCCANCELLED POST MARKETDIN 01979582
APO-GEMFIBROZIL CAP 300MG USP300 MGCAPSULEAPOTEX INCCANCELLED POST MARKETDIN 01979574
DOM-GEMFIBROZIL300 MGCAPSULEDOMINION PHARMACALCANCELLED POST MARKETDIN 02241608
DOM-GEMFIBROZIL600 MGTABLETDOMINION PHARMACALCANCELLED POST MARKETDIN 02230580
GEMFIBROZIL CAP 300MG300 MGCAPSULEOMNI LABORATORIES DIVISION, WARNER-LAMBERT CANADA INC.CANCELLED POST MARKETDIN 00851922
GEMFIBROZIL TAB 600MG600 MGTABLETOMNI LABORATORIES DIVISION, WARNER-LAMBERT CANADA INC.CANCELLED POST MARKETDIN 00851930
GEMFIBROZIL-300 - CAP300 MGCAPSULEPRO DOC LIMITEECANCELLED POST MARKETDIN 02136031
LOPID 600MG600 MGTABLETPFIZER CANADA ULCCANCELLED POST MARKETDIN 00659606
LOPID CAP 300MG300 MGCAPSULEPFIZER CANADA ULCCANCELLED POST MARKETDIN 00599026

Who else supplies GEMFIBROZIL worldwide?

Nexara tracks national medicine registries and published price lists across multiple markets. GEMFIBROZIL appears in 24 registered pack listings across 9 markets, published on 8 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.

Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.

How much does GEMFIBROZIL cost around the world?

GEMFIBROZIL is listed on 9 national price registers Nexara tracks, across 42 pack listings published on 8 different price bases. What each country publishes is set out below.

MarketWhat that country publishesBrands listedPack listingsAs of
United Statesacquisition12303 Sep 2026
Italyprezzo al pubblico (classe A)5702 Sep 2026
Australiaex-manufacturer2408 Sep 2026
AustriaKVP (Kassenverkaufspreis)1203 Sep 2026
Bahrainretail (max)2201 Sep 2026
United Arab Emiratespublic1131 Aug 2026
Greeceproducer price (ex-factory)1103 Sep 2026
Saudi Arabiapublic1101 Sep 2026
South Africasingle exit price1101 Sep 2026

Why there are no figures here. These bases are not comparable. A Brazilian ex-factory ceiling, a Belgian pharmacy public price and a Japanese reimbursement rate answer three different questions, and none of them is what a product lands in Canada for. Putting them side by side would mislead in both directions, so Nexara publishes where a molecule is listed and on what basis, and quotes the delivered Canadian price per order.

Ask Nexara for a landed Canadian price

Can this still be bought in Canada?

No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.

If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative

Ordering questions

Who can buy this from Nexara?

Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.

Is there a minimum order?

Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.

What is the lead time?

Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.

Can Nexara supply this for a clinical trial?

Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.

Health Canada Drug Product Database (DPD), DIN 02136058. Last reviewed 2026-09-10. Nexara Health is a licensed wholesaler and supplies licensed entities only; consumer orders are routed to a partner pharmacy.